of Titan's gases. A potential explanation for the polar HCN clouds is that they form from a process known as open-cell convection, in which cool, dense air sinks and warms slightly while the surrounding air rises and cools, thereby forming clouds (Fig. 1) . The cool polar atmosphere also contrasts with the warmer lower latitudes. The resulting decrease in temperature with increasing latitude affects the atmosphere's pressure structure, which, when combined with Titan's spin, implies circumpolar winds that become more strongly westerly with altitude 12 . Titan's atmospheric polar vortex, witnessed by the rapid spin of the south polar HCN cloud, isolates the polar air from the rest of the atmosphere, allowing the pole to cool further. The presence of clouds spinning in a vortex can thus naturally emerge at a winter pole.
However, the detailed operations of Titan's winter pole, such as the seasonal evolution of the chemistry and temperature at 300 km altitude, are complicated and far from understood 12 . Better grasped is Earth's polar atmosphere, where the winter polar vortex is a repository of unique composition and clouds. The polar chemistry evolves from winter to spring with the production and loss of many molecular species that ultimately control the polar ozone abundances.
Laboratory simulations suggest that the photochemistry in Titan's atmosphere produces amino acids and nucleotide bases 13 . How far the chemistry evolves in Titan's upper atmosphere is unclear, and would probably require detailed in situ sampling of the upper atmosphere. However, further understanding of Titan's organic chemistry will entail studies of the abundance, phase and particulate composition of the main nitrogen photochemical product, which affects the overall nitrogen chemistry. in organic lakes and puddles, with a 'soup base' of methane and ethane (C 2 H 6 ) that resembles natural gas 7, 8 . As these nitrogen-bearing molecules diffuse downward, they are steered towards Titan's winter pole by atmospheric circulation 9 . Here they enter cooler regions and condense into clouds at different atmospheric layers, depending on their different thermodynamic properties.
Two distinct kinds of cloud cap the winter pole, both identified from measurements made by Cassini's Visual and Infrared Mapping Spectrometer: one at 55 km altitude, which is consistent with a C 2 H 6 composition 10 , and one at 300 km, found by de Kok and colleagues to be made of HCN. These stacked clouds, composed of the most abundant nitrogen and carbon photo chemical species, track seasonally with the winter pole. An HCN cloud was previously identified 8 above Titan's north pole at the end of the northern winter, and the C 2 H 6 cloud has vanished from this region in preparation for its southerly migration for the winter 11 . The winter pole on Titan is a peculiar place. Here the atmosphere radiatively cools during winter's darkness, triggering a suite of dynamical atmospheric responses. As discussed by de Kok and colleagues, the polar temperature is regulated by the intertwined effects of atmospheric chemistry, radiation and dynamics, which control the atmosphere's absorption and emission of radiation, and the compression, expansion and mixing 2 find that this spinning cloud, which completes an orbit in 9 hours -much faster than Titan's 15-day orbit -is composed of hydrogen cyanide. This orbital period signals the formation of a polar vortex as the southern pole enters into winter darkness 14 . The image, taken by the Cassini spacecraft's Imaging Subsystem, is centred near the south pole and extends over a distance of about 1,000 kilometres.
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Ebola therapy protects severely ill monkeys
A blend of three monoclonal antibodies has completely protected monkeys against a lethal dose of Ebola virus. Unlike other post-infection therapies, the treatment works even at advanced stages of the disease. See Article p.47
T H O M A S W. G E I S B E R T
T he filoviruses known as Ebola virus and Marburg virus are among the most deadly of pathogens, with fatality rates of up to 90% (ref. 1) . Early this year, a new strain of the Zaire species of Ebola virus emerged 2 in the West African country of Guinea and quickly spread to Liberia, Sierra Leone and Nigeria. The outbreak persists despite the best efforts of local and international authorities, and is now the largest filovirus outbreak on record, with no end in sight. There are no licensed vaccines or post-exposure treatments against Ebola, so moving the most promising interventions forward is a matter of utmost urgency. On page 47 of this issue, Qiu et al. 3 report that rhesus monkeys can be completely protected from lethal Ebola infection using ZMapp -a blend of three monoclonal antibodies. Crucially, the treatment protected monkeys even when it was admini stered as late as 5 days after exposure to the virus, at a time when the animals were severely ill.
Since the discovery of Ebola virus (Fig. 1 ) in 1976, researchers have been actively developing treatments to combat infection. Studies over the past decade have found that modulators of blood coagulation 4, 5 , an antisense oligo nucleotide called AVI-6002 (ref. 6 ) and a vaccine 7 based on vesicular stomatitis virus (VSV) all afforded partial protection of monkeys against Ebola when administered within an hour of virus exposure. The VSV-based vaccine was used in 2009 to treat a laboratory worker in Germany shortly after she was accidentally pricked with a needle possibly contaminated by an Ebola-infected animal 8 . The worker survived, but it is unclear whether this was because she had not been exposed to Ebola or because the vaccine protected her.
Subsequent advances have been made in developing treatments that can completely protect monkeys against Ebola. These include small 'interfering' RNAs (known as TKMEbola 9 ) and various combinations of antibodies [10] [11] [12] . But these treatments need to be administered within 2 days of exposure to the virus. So although these approaches were highly important and can be used to treat known exposures, the need for treatments that protect at later times after infection was paramount.
Further development and improvement of the antibody-based strategies led to a cocktail of monoclonal antibodies 13 that protected 43% of monkeys when given as late as 5 days after Ebola exposure -a time at which the clinical signs of disease are apparent. Another therapy that combines monoclonal antibodies with interferon-α (a protein that stimulates an antiviral response) provides almost complete protection of macaques when given 3 days after exposure 14 , at which point the virus can be detected but clinical signs are only just beginning to be seen in some animals. Qiu et al. now report ZMapp, an antibody therapy that does not require interferon-α, and which was developed by two collaborating teams of researchers who had worked on some of the previously reported antibody treatments. ZMapp was made by testing different combinations of chimaeric mono clonal antibodies (in which fragments of human antibodies are attached to antibody fragments from mice). The optimal formulation contains two antibodies from a previously reported blend 14 and a third from a different cocktail 13 . To test the therapy, Qiu et al. administered a lethal dose of Ebola virus to three groups of six animals, and then treated them with three doses of ZMapp. The first group received therapy at 3, 6 and 9 days post-infection; the second group at 4, 7 and 10 days; and the third group at 5, 8 and 11 days. Remarkably, all the animals survived, and were found to have undetectable viral loads by 21 days after infection. It should be noted that the authors used the Kikwit variant of the virus in these experiments, because the Guinean strain from the current West African outbreak was not available in time for this part of their study. However, they went on to show that ZMapp inhibits replication of the Guinean strain in cell culture.
The development of ZMapp and its success in treating monkeys at an advanced stage of Ebola infection is a monumental achievement. On this basis, the treatment has been used in the current Ebola outbreak to treat several patients on compassionate grounds 15 . Of these, two US health-care workers have recovered -but whether ZMapp had any effect is unknown, because at the time of writing, about 45% of patients in this outbreak survive without treatment 16 . As of 26 August, two other patients treated with ZMapp have not survived, but this might be because the treatment was initiated too late in the course of the disease.
The diversity of strains and species of Ebola and Marburg viruses remain an obstacle for all candidate treatments. Lethal disease in humans is caused by three different species of Ebola virus (Sudan, Bundibugyo and Zaire) and two genetically distinct lineages of Marburg virus. Treatments that protect against one species of Ebola -Zaire, in the case of ZMappwill probably not protect against a different species of the virus, and might not protect against a different strain within a species.
Although the need for treatments for filovirus infections is unquestionable, the most effective way to manage and control future outbreaks might be through preventive vaccines, some of which have been tailored to protect against multiple species and strains. During outbreaks, single-injection vaccines are needed to ensure rapid use and protection. At least five preventive vaccines have been shown to completely protect monkeys against Ebola and Marburg infection 17 . But only VSV-based vaccines have been reported to completely protect monkeys against Ebola (Zaire) virus after a single injection 18 -notably, the wild-type virus, rather than a cultured variant that has also been used in research, and which produces slower disease progression in macaques.
Antibody therapies and several other strategies mentioned here should ultimately be included in an arsenal of interventions for controlling future Ebola outbreaks. Although ZMapp in particular has been administered for compassionate use, the next crucial step will be to formally assess its safety and effectiveness. Testing the latter is clearly difficult, because intentional infection of human subjects in clinical trials is not possible. US regulations, however, could allow the treatment to be licensed for widespread use on the basis of safety testing in humans and efficacy testing in animals. In the long run, the manufacture of ZMapp could require investment in infrastructure for making monoclonal antibodies at an industrial scaleassuming that funding is available to pay the production costs. 
THOMAS W. GEISBERT
There are many puzzles about left handedness. Left handers are often less consistent in using the left hand than right handers in using the right; the incidence of left handedness is raised in many pathological groups and yet left handers may be of high intelligence; several different solutions have been offered to the problem of which cerebral hemisphere leads in speech functions in left handers; left handers seem to be more likely to recover from aphasias than right handers. It is the purpose of this article to describe a model of the inheritance of handedness and cerebral dominance which, together with a hypothesis about the direction of shifts of dominance, might account for many puzzling facts. From Nature 3 October 1964
Years Ago
Every important town in Great Britain has established at least one great technical college at large cost in building and apparatus, with staffs of professors and teachers (always badly paid), and it is found that for their first two years the students have to be kept at great cost to the country learning those simple principles of science which they ought to have learnt at school. It is found that they are not only ignorant, but they have none of the habits of thought and scientific method which school laboratory work induces. The clever ones, if they leave school at seventeen, recover from the effects of a school education which prepared men only for being lawyers or clergyman; but the average man finds that he has been prepared only to be a hewer of wood and a drawer of water to the real engineer. From Nature 1 October 1914
A sk an astronomer when quasars were at their peak and they will probably tell you it was about 10 billion years ago, when the Universe was about one-third of its current size 1, 2 . Before then, the quasar population was still growing along with other large structures in the young Universe; there has since been a steady decrease in quasar numbers. However, in a paper published in The Astrophysical Journal, Vardanyan et al. 3 present results suggesting that this widely accepted picture may not be correct -or at least that it does not tell the whole story.
That story started in 1963 with the discovery 4,5 of a new type of astronomical object, referred to variously as quasi-stellar objects or quasars, the name that is generically used today. Their physical nature was initially unknown, but it was gradually deduced 6 that a quasar is a glowing disk of hot, dense material that can form around the supermassive black hole at the centre of a large galaxy, often the result of a collision with a second galaxy. Although such accretion disks are 'only' about the size of the Solar System, they can outshine all the stars in the host galaxy by a factor of a thousand or so. Quasars can hence be seen comparatively easily at great distances, which makes it possible to trace their evolution back to the first billion years after the Big Bang.
More than a million quasars have been catalogued in the 50 years since their discovery. Although this is more than enough for most demographic studies of astronomical objects, it is difficult to obtain a representative sample of quasars that spans a wide range of distances from Earth, and hence cosmic look-back times. It is also challenging to properly account for all the energy output of a quasar, because some of the ultraviolet light that is emitted from the accretion disk is absorbed by dust in the host galaxy and re-radiated at much longer, infrared wavelengths. Most surveys of the quasar population have been undertaken using observations made at optical or near-infrared wavelengths (between about 0.2 and 2 micrometres), and it is these types of measurement that have provided the strongest evidence that quasar numbers peaked fairly sharply 10 billion years ago.
Vardanyan and colleagues studied a comparatively small sample of 10,000 quasars that were initially identified using optical data from the Sloan Digital Sky Survey. But, crucially, the authors had access to longer wavelength measurements (at about 8 μm) of the same objects from the Wide-Field Infrared Survey Explorer (WISE) satellite. They were thus able to get a more complete census of the quasars' energy output and, after correcting for the various complicated observational selection effects that inevitably make such studies so difficult, found some striking results. They confirmed the steady decrease in the quasar population over the past 10 billion years but, rather than the expected drop at cosmic times before 3 billion years, they found a 'plateau' in the quasars' energy output back to a little over a billion years after the Big Bang (Fig. 1) . The authors were unable to probe any earlier than this, and one of their conclusions was that extending these sorts of measurements to earlier times is the best way to explore this issue further.
These results are not unprecedented -there have been several similar previous claims 7, 8 that the canonical understanding of the quasar population from optical data was incomplete. However, the scale and quality of the WISE data are superior to any previously available. The findings demand serious attention, both
